Back to results
US 9,993,565 B2Granted
Method for treating IFNalpha related conditions
AssigneeNeovacs
InventorsGeraldine Grouard-Vogel, Olivier Dhellin, Bernard Fanget, Pierre Vandepapeliere, Camille Roucairol
Life of this patent
Estimating the term…
Abstract
An immunogenic product including IFNα coupled to a carrier protein molecule is capable to induce in vivo anti-IFNα antibodies and is useful in treating IFNα related conditions.
Claims13
A method for treating systemic lupus erythematosus (SLE), Sjögren syndrome, type I diabetes, dermatomyositis and/or polymyositis in a subject in need thereof, by raising antibody levels against IFNα, the method comprising administering to the subject a therapeutically effective amount of an immunogenic product comprising IFNα coupled to keyhole limpet hemocyanin (KLH),
- wherein said therapeutically effective amount is in the range of from 60 mcg to 240 mcg of immunogenic product per administration, and wherein the weight ratio of IFNα/KLH is in the range of 0.06 to 0.6, and
- wherein said treating means at least one selected from the group consisting of alleviating symptoms, suppressing, diminishing or inhibiting any direct or indirect pathological consequences of the IFNα related condition, lowering the rate of progression of the IFNα related condition, ameliorating or palliating the state of the IFNα related condition, causing remission, maintaining remission state and improving prognosis.
Dependencies are inferred from the claim text.